View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 5, 2021updated 12 Jul 2022 11:21am

Johnson & Johnson expands Covid-19 vaccine trial to adolescents

Johnson & Johnson (J&J) has expanded Phase IIa clinical trial of Covid-19 vaccine candidate to include adolescent subjects aged 12 to 17 years. 

Johnson & Johnson (J&J) has expanded Phase IIa clinical trial of Covid-19 vaccine candidate to include adolescent subjects aged 12 to 17 years.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, the single-shot vaccine is authorised for emergency use for active immunisation to prevent Covid-19 in adults.

The randomised, double-blind, placebo-controlled study had begun in September last year. It was primarily designed to assess the safety, reactogenicity and immunogenicity of single-dose and two-dose regimens of the vaccine candidate in healthy adults aged 18 to 55 years and elderly individuals aged 65 years and above.

It will also analyse possible vaccination schedules at one, two and three-month intervals in two-dose vaccine regimens.

Johnson & Johnson executive committee vice-chairman and chief scientific officer Paul Stoffels said: “The Covid-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing.

“It is vital that we develop vaccines for everyone, everywhere, to help combat the spread of the virus with the goal to return to everyday life.”

In the initial stage, the vaccine candidate will be evaluated in a smaller number of adolescents. On reviewing the initial data from the Phase IIa trial, the study will be extended to a bigger group of younger adolescents in a stepwise manner.

Currently, the trial is enrolling subjects in Spain and the UK, with enrolment set to begin in the US, the Netherlands and Canada, Brazil and Argentina soon.

Johnson & Johnson Janssen Research & Development global head Mathai Mammen said: “In addition to expanding this ongoing study to include adolescents, we are in discussions with health authorities and are hard at work to initiate studies in pregnant women and children in the near future.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena